Skip to search formSkip to main contentSkip to account menu

vilanterol

Known as: 4-(2-((6-((2-(((2,6-dichlorophenyl)methyl)oxy)ethyl)oxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol, 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol, vilantérol 
National Institutes of Health

Related topics

Related topics

8 relations
7 ACTUAT umeclidinium 0.0625 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder InhalerAdrenergic beta2-Agonists [MoA]fluticasone / vilanterolumeclidinium / vilanterol

Broader (2)

Benzyl AlcoholsChlorobenzenes

Narrower (1)

vilanterol trifenatate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort…
Background and objective Retrospective claims data in patients with chronic obstructive pulmonary disease (COPD) initiating… 
Review
2018
Review
2018
Optimal Bronchodilation for COPD Patients: Are All Long-Acting β2-Agonist/Long-Acting Muscarinic Antagonists the Same?
Bronchodilators provide improvements in lung function and reductions in symptoms and exacerbations, and are the mainstay of… 
Review
2018
Review
2018
Treating asthma exacerbations in athletes: TUE or not TUE?
2017
2017
The effect of umeclidinium on lung function and symptoms in patients with fixed airflow obstruction and reversibility to salbutamol: A randomised, 3-phase study.
Review
2016
Review
2016
Vilanterol and fluticasone furoate for asthma.
BACKGROUND Vilanterol (VI) is a long-acting beta2-agonist (LABA) that binds to the beta2-adrenoceptor on the airway smooth muscle… 
Review
2016
Review
2016
Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity, mortality, and health care expenditure worldwide… 
2014
2014
Population Pharmacokinetics of Inhaled Umeclidinium and Vilanterol in Patients with Chronic Obstructive Pulmonary Disease
Background and objectivesA fixed-dose combination of the bronchodilators umeclidinium and vilanterol is in development for the… 
2013
2013
Inhaled fluticasone furoate/vilanterol does not affect hypothalamic-pituitary-adrenal axis function in adolescent and adult asthma: randomised, double-blind, placebo-controlled study
Fluticasone furoate (FF) is a novel inhaled corticosteroid with 24‐h activity. FF is in development as a once‐daily treatment for… 
2013
2013
The safety, pharmacokinetics and pharmacodynamics of a combination of fluticasone furoate and vilanterol in healthy Japanese subjects.
OBJECTIVE To evaluate the safety, pharmacokinetics and pharmacodynamics of fluticasone furoate (FF) and vilanterol (VI… 
2011
2011
The safety, tolerability, pharmacodynamics and pharmacokinetics of inhaled fluticasone furoate (FF) and vilanterol (VI) are unaffected by administration in combination
Introduction: A combination of the novel corticosteroid FF and long acting beta 2 -agonist VI (FF/VI) is currently under… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)